{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:50:03Z","timestamp":1787165403851,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070927"],"award-info":[{"award-number":["32070927"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MC121"],"award-info":[{"award-number":["ZR2023MC121"]}],"id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011482","name":"Yantai Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023JCYJ060"],"award-info":[{"award-number":["2023JCYJ060"]}],"id":[{"id":"10.13039\/501100011482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011482","name":"Yantai Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023JCYJ064"],"award-info":[{"award-number":["2023JCYJ064"]}],"id":[{"id":"10.13039\/501100011482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13346-024-01540-x","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:02:11Z","timestamp":1709888531000},"page":"3186-3199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA"],"prefix":"10.1007","volume":"14","author":[{"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8203-7361","authenticated-orcid":false,"given":"Yuanlei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"issue":"(10207)","key":"1540_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/s0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467\u20131480.\u00a0https:\/\/doi.org\/10.1016\/s0140-6736(19)32319-0.","journal-title":"Lancet"},{"issue":"7","key":"1540_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/cm9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u2013791. https:\/\/doi.org\/10.1097\/cm9.0000000000001474.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"1540_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/cm9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u2013590. https:\/\/doi.org\/10.1097\/cm9.0000000000002108.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"1540_CR4","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/jci80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391. https:\/\/doi.org\/10.1172\/jci80011.","journal-title":"J Clin Invest"},{"issue":"19","key":"1540_CR5","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.Ccr-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-3271.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1540_CR6","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","volume":"19","author":"YX Zhang","year":"2019","unstructured":"Zhang YX, Zhao YY, Shen J, et al. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy. Nano Lett. 2019;19(5):2774\u20132783. https:\/\/doi.org\/10.1021\/acs.nanolett.8b04296.","journal-title":"Nano Lett"},{"issue":"14","key":"1540_CR7","doi-asserted-by":"publisher","first-page":"e1805888","DOI":"10.1002\/adma.201805888","volume":"31","author":"F Zhou","year":"2019","unstructured":"Zhou F, Feng B, Yu H, et al. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade. Adv Mater. 2019;31(14):e1805888. https:\/\/doi.org\/10.1002\/adma.201805888.","journal-title":"Adv Mater"},{"issue":"6","key":"1540_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10147-019-01425-x","volume":"24","author":"G Wang","year":"2019","unstructured":"Wang G, Yang B, Fu Z, et al. Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. Int J Clin Oncol. 2019;24(6):614\u2013623. https:\/\/doi.org\/10.1007\/s10147-019-01425-x.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1540_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00280-015-2901-x","volume":"77","author":"P Perego","year":"2016","unstructured":"Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol. 2016;77(1):5\u201318. https:\/\/doi.org\/10.1007\/s00280-015-2901-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1540_CR10","doi-asserted-by":"publisher","first-page":"2171158","DOI":"10.1080\/10717544.2023.2171158","volume":"30","author":"Y Fu","year":"2023","unstructured":"Fu Y, Kong Y, Li X, et al. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy. Drug Deliv. 2023;30(1):2171158. https:\/\/doi.org\/10.1080\/10717544.2023.2171158.","journal-title":"Drug Deliv"},{"key":"1540_CR11","doi-asserted-by":"publisher","first-page":"113927","DOI":"10.1016\/j.ejmech.2021.113927","volume":"227","author":"M Mu","year":"2022","unstructured":"Mu M, Zhan J, Dai X, et al. Research progress of azido-containing Pt(IV) antitumor compounds. Eur J Med Chem. 2022;227:113927. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113927.","journal-title":"Eur J Med Chem"},{"key":"1540_CR12","doi-asserted-by":"publisher","unstructured":"Venkatesh V, Sadler PJ. Platinum(IV) prodrugs. Met Ions Life Sci. 2018;18:69\u2013108. https:\/\/doi.org\/10.1515\/9783110470734-009.","DOI":"10.1515\/9783110470734-009"},{"issue":"10","key":"1540_CR13","doi-asserted-by":"publisher","first-page":"e202200695","DOI":"10.1002\/cbdv.202200695","volume":"19","author":"X Liu","year":"2022","unstructured":"Liu X, Barth MC, Cseh K, et al. Oxoplatin-based Pt(IV) Lipoate complexes and their biological activity. Chem Biodivers. 2022;19(10):e202200695. https:\/\/doi.org\/10.1002\/cbdv.202200695.","journal-title":"Chem Biodivers"},{"key":"1540_CR14","doi-asserted-by":"publisher","first-page":"115515","DOI":"10.1016\/j.ejmech.2023.115515","volume":"257","author":"X Liu","year":"2023","unstructured":"Liu X, Wenisch D, Dahlke P, et al. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs. Eur J Med Chem. 2023;257:115515. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115515.","journal-title":"Eur J Med Chem"},{"key":"1540_CR15","doi-asserted-by":"publisher","first-page":"102002","DOI":"10.1016\/j.pupt.2021.102002","volume":"65","author":"RW Chapman","year":"2020","unstructured":"Chapman RW, Corboz MR, Malinin VS, et al. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020;65:102002. https:\/\/doi.org\/10.1016\/j.pupt.2021.102002.","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"1540_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1359-6101(01)00032-6","volume":"13","author":"MP Colombo","year":"2002","unstructured":"Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155\u201368. https:\/\/doi.org\/10.1016\/s1359-6101(01)00032-6.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"16","key":"1540_CR17","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1158\/1078-0432.Ccr-07-0776","volume":"13","author":"M Del Vecchio","year":"2007","unstructured":"Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13(16):4677\u201385. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0776.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1540_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, Woodcock MG, Barragan G, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15(1):89. https:\/\/doi.org\/10.1038\/s41467-023-44310-y.","journal-title":"Nat Commun"},{"issue":"23","key":"1540_CR19","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1158\/1078-0432.Ccr-20-3250","volume":"26","author":"A Cirella","year":"2020","unstructured":"Cirella A, Berraondo P, Di Trani CA, et al. Interleukin-12 message in a bottle. Clin Cancer Res. 2020;26(23):6080\u20136082. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3250.","journal-title":"Clin Cancer Res"},{"issue":"(1\u20132)","key":"1540_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11010-016-2687-0","volume":"415","author":"Q Wang","year":"2016","unstructured":"Wang Q, Cheng F, Ma TT, et al. Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. Mol Cell Biochem. 2016;415(1\u20132):157\u201368. https:\/\/doi.org\/10.1007\/s11010-016-2687-0.","journal-title":"Mol Cell Biochem"},{"issue":"23","key":"1540_CR21","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1158\/1078-0432.Ccr-20-0472","volume":"26","author":"SL Hewitt","year":"2020","unstructured":"Hewitt SL, Bailey D, Zielinski J, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res. 2020;26(23):6284\u20136298. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0472.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1540_CR22","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.7150\/thno.77259","volume":"12","author":"HN Jung","year":"2022","unstructured":"Jung HN, Lee SY, Lee S, et al. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging. Theranostics. 2022;12(17):7509\u20137531. https:\/\/doi.org\/10.7150\/thno.77259.","journal-title":"Theranostics"},{"key":"1540_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","volume":"345","author":"JQ Liu","year":"2022","unstructured":"Liu JQ, Zhang C, Zhang X, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306\u2013313. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.021.","journal-title":"J Control Release"},{"issue":"23","key":"1540_CR24","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","volume":"54","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang Y, Dong Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283\u20134293. https:\/\/doi.org\/10.1021\/acs.accounts.1c00550.","journal-title":"Acc Chem Res"},{"issue":"2","key":"1540_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, Burkhard SH, Ohs I, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237\u201346. https:\/\/doi.org\/10.1038\/cdd.2014.134.","journal-title":"Cell Death Differ"},{"issue":"41","key":"1540_CR26","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1002\/adfm.201602963","volume":"26","author":"B Feng","year":"2016","unstructured":"Feng B, Zhou FY, Xu ZA, et al. Versatile prodrug nanoparticles for acid-triggered precise imaging and organelle-specific combination cancer therapy. Adv Funct Mater. 2016;26(41):7431\u20137442. https:\/\/doi.org\/10.1002\/adfm.201602963.","journal-title":"Adv Funct Mater"},{"issue":"1","key":"1540_CR27","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1080\/10717544.2021.1938754","volume":"28","author":"T Lang","year":"2021","unstructured":"Lang T, Li N, Zhang J, et al. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro. Drug Deliv. 2021;28(1):1272\u20131280. https:\/\/doi.org\/10.1080\/10717544.2021.1938754.","journal-title":"Drug Deliv"},{"key":"1540_CR28","doi-asserted-by":"publisher","first-page":"1161507","DOI":"10.3389\/fimmu.2023.1161507","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li D, Shen Y, et al. Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB\/c mice against acute toxoplasmosis. Front Immunol. 2023;14:1161507. https:\/\/doi.org\/10.3389\/fimmu.2023.1161507.","journal-title":"Front Immunol"},{"issue":"4","key":"1540_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"1540_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.omtn.2019.06.011","volume":"17","author":"H Huysmans","year":"2019","unstructured":"Huysmans H, De Temmerman J, Zhong Z, et al. Improving the repeatability and efficacy of intradermal electroporated self-replicating mRNA. Mol Ther Nucleic Acids. 2019;17:388\u2013395. https:\/\/doi.org\/10.1016\/j.omtn.2019.06.011.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"1540_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/vaccines1030367","volume":"1","author":"Y Cu","year":"2013","unstructured":"Cu Y, Broderick KE, Banerjee K, et al. Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines (Basel). 2013;1(3):367\u201383. https:\/\/doi.org\/10.3390\/vaccines1030367.","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"1540_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1039\/c8bm01501e","volume":"7","author":"B Li","year":"2019","unstructured":"Li B, Cai M, Lin L, et al. MRI-visible and pH-sensitive micelles loaded with doxorubicin for hepatoma treatment. Biomater Sci. 2019;7(4):1529\u20131542. https:\/\/doi.org\/10.1039\/c8bm01501e.","journal-title":"Biomater Sci"},{"issue":"3","key":"1540_CR33","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.21037\/apm-21-65","volume":"10","author":"XN Wang","year":"2021","unstructured":"Wang XN, Li Y, Meng L, et al. Evaluation of influence of telmisartan on the pharmacokinetics and tissue distribution of canagliflozin in rats and mice. Ann Palliat Med. 2021;10(3):3086\u20133096. https:\/\/doi.org\/10.21037\/apm-21-65.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"1540_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12944-018-0911-5","volume":"17","author":"T Li","year":"2018","unstructured":"Li T, Qian Y, Li H, et al. Combination of serum lipids and cancer antigens as a novel marker for colon cancer diagnosis. Lipids Health Dis. 2018;17(1):261. https:\/\/doi.org\/10.1186\/s12944-018-0911-5.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"1540_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12957-023-03079-6","volume":"21","author":"X Zhang","year":"2023","unstructured":"Zhang X, Qin H, Tan X, et al. Predictive value of monocyte to high-density lipoprotein cholesterol ratio and tumor markers in colorectal cancer and their relationship with clinicopathological characteristics. World J Surg Oncol. 2023;21(1):200. https:\/\/doi.org\/10.1186\/s12957-023-03079-6.","journal-title":"World J Surg Oncol"},{"key":"1540_CR36","doi-asserted-by":"publisher","first-page":"175883591990087","DOI":"10.1177\/1758835919900872","volume":"12","author":"JM Riedl","year":"2020","unstructured":"Riedl JM, Posch F, Prager G, et al. The AST\/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Ther Adv Med Oncol. 2020;12:1758835919900872. https:\/\/doi.org\/10.1177\/1758835919900872.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"1540_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1747-0285.2010.00950.x","volume":"75","author":"MS Bahia","year":"2010","unstructured":"Bahia MS, Silakari O. Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem Biol Drug Des. 2010;75(5):415\u201343. https:\/\/doi.org\/10.1111\/j.1747-0285.2010.00950.x.","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"1540_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R van Horssen","year":"2006","unstructured":"van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397\u2013408. https:\/\/doi.org\/10.1634\/theoncologist.11-4-397.","journal-title":"Oncologist"},{"issue":"6","key":"1540_CR39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1213\/ane.0000000000005175","volume":"131","author":"A Margraf","year":"2020","unstructured":"Margraf A, Ludwig N, Zarbock A, et al. Systemic inflammatory response syndrome after surgery: mechanisms and protection. Anesth Analg. 2020;131(6):1693\u20131707. https:\/\/doi.org\/10.1213\/ane.0000000000005175.","journal-title":"Anesth Analg"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01540-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01540-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01540-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T10:11:55Z","timestamp":1727777515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01540-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01540-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3490912\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"8 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments reported in this paper were approved by the Committee on the Ethics of Animal Experiments of the Yantai Institute of Materia Medica, and were performed in strict accordance with the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors provided consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}